Exciting New Treatment for Depression
HOPE Therapeutics, Inc., an innovative subsidiary under NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has made a groundbreaking announcement regarding the initiation of the ONE-D protocol for treating treatment-resistant depression. This transformative approach marks a significant milestone in psychiatric care, as it aims to change the lives of countless individuals battling severe depression.
What is the ONE-D Protocol?
At the heart of this initiative is the ONE-D protocol, which stands for One Day. This treatment promises to achieve remarkable results, helping patients reach remission from treatment-resistant depression all within a single day. This is not only a milestone for the field of psychiatry but also offers hope for patients who have struggled with traditional methods of therapy.
How Does It Work?
The ONE-D protocol employs an FDA-cleared device that utilizes Transcranial Magnetic Stimulation (TMS), a non-invasive procedure that stimulates specific regions of the brain responsible for mood regulation. This device is paired with physician-prescribed medications, including D-cycloserine and lisdexamfetamine, which have shown promising results. Preliminary findings from various studies suggest that patients have reported an 87% response rate and 72% remission rate after just six weeks of treatment.
Innovative Deployment Across Florida
HOPE Therapeutics has swiftly expanded its TMS services in Florida, deploying the ONE-D protocol across multiple locations, including Fort Myers and Sarasota. By the end of 2025, HOPE aims to establish a total of six locations throughout the state, making its transformative treatment more accessible to those in need. Dr. Rebecca Cohen, the Medical Director of HOPE, is leading this initiative as Florida's first Ampa-certified psychiatrist, reinforcing the dedication to providing cutting-edge mental health care.
Advancements in Mental Health Treatment
The release of the ONE-D protocol reflects a larger movement in the mental health field, where innovative treatments are becoming more prevalent. Traditional TMS protocols required patients to undergo 90 days of therapy, which can be a daunting obstacle for those seeking immediate relief from debilitating depression. The introduction of a rapid, effective treatment like ONE-D can significantly enhance the lives of patients, especially since millions of Americans face the toll of severe depression annually.
A Commitment to Patient Care
Dr. Cohen expressed enthusiasm about leading HOPE Therapeutics at this pivotal moment, stating that patients can experience a substantial healing transformation in a matter of weeks rather than months. While the results from various studies are yet to be fully randomized and prospective, they suggest remarkable promise and the potential to revolutionize TMS therapy.
About HOPE Therapeutics
HOPE Therapeutics, Inc. is dedicated to establishing a premier network of interventional psychiatry clinics that deliver groundbreaking therapies for severe depression and related disorders. Their services include ketamine treatments, TMS therapies, and a range of other innovative mental health interventions. By leveraging contemporary neuroplastic medications alongside their digital therapeutic platform, HOPE is not only addressing the immediate symptoms of suicidal depression but also fortifying patients’ long-term mental health outcomes.
Conclusion
HOPE Therapeutics is poised to change the landscape of depression treatment with its ONE-D protocol. As the organization continues to roll out this innovative approach across Florida, a greater number of individuals may find the relief they have long sought. This development highlights the significant strides being made in mental health care, fostering hope for many who struggle with treatment-resistant depression.
Frequently Asked Questions
What is the ONE-D protocol?
The ONE-D protocol is a groundbreaking treatment method that combines TMS and physician-prescribed medications to achieve remission from treatment-resistant depression in just one day.
Where is the ONE-D protocol available?
Currently, the ONE-D protocol is available at multiple HOPE Therapeutics locations across Florida, including Sarasota, Fort Myers, and Naples.
What are the success rates of the ONE-D protocol?
Initial nonrandomized studies indicate a response rate of 87% and a remission rate of 72% following treatment over six weeks.
Who leads the ONE-D protocol at HOPE?
Dr. Rebecca Cohen, the Medical Director of HOPE Therapeutics, is leading the implementation of the ONE-D protocol as the first Ampa-certified psychiatrist in Florida.
What is the aim of HOPE Therapeutics?
HOPE Therapeutics aims to provide cutting-edge mental health treatments while significantly enhancing patient care and outcomes for those with severe depression and related issues.
